バーテックス・ファーマシューティカルズに関するコメント

$バーテックス・ファーマシューティカルズ(VRTX.US)$
NEWS
Vertex Pharmaceuticals Inc expected to post earnings of $4.06 a share - Earnings Preview
Vertex Pharmaceuticals Inc VRTX.OQ VRTX.O is expected to show a rise in quarterly revenue when it reports results on May 6 for the period ending March 31 2024
The Boston Massachusetts-based company is expected to report a 8.6% increase in revenue to $2.579 billion from $2.37 billion a year ago, according to the mean estimate from 23 analysts, based on LSEG data.
​LSEG's...

$バーテックス・ファーマシューティカルズ(VRTX.US)$
NEWS
Vertex Pharmaceuticals Inc - Treefrog Will Also Receive up to $215M in Milestones

$バーテックス・ファーマシューティカルズ(VRTX.US)$
NEWS
Vertex Pharmaceuticals Inc - Under Agreement, Treefrog Will Receive a $25M Upfront Payment, an Equity Investment From Vertex
Vertex Will Fund All Research and Development Costs Related to Collaboration

$バーテックス・ファーマシューティカルズ(VRTX.US)$
NEWS
Vertex and Treefrog Therapeutics Announce Licensing Agreement and Collaboration to Optimize Production of Vertex's Cell Therapies for Type 1 Diabetes

$ノババックス(NVAX.US)$$モデルナ(MRNA.US)$
April 18, 2024
For Global Investor Audience Only
Novavax’s Nuvaxovid XBB.1.5 dispersion for injection, COVID-19 Vaccine (recombinant, adjuvanted) (NVX-CoV2601) is now available to pharmacies across the United Kingdom (U.K.) for private healthcare providers to offer an updated protein-based non-mRNA option as part of the 2024 vaccination season.  
To...

$プロキドニー(PROK.US)$ sank more than 15% Thursday as the biotech snapped a five-session winning streak that saw its price rise some 130% in just days.
PROK fell 15.5% to close at $2.40, ending a run-up that began last Thursday, April 11, despite no apparent news.
Shares gained 132.4% between the stock's $1.45 close on April 10 and its $3.37 peak this past Wednesday.
ProKidney, which is trying t...

$プロキドニー(PROK.US)$ rose more than 30% Tuesday as the biotech firm rallied for the fourth straight session – a run-up that's seen the stock rise nearly 90% in less than a week.
PROK gained 30.1% to close at $2.72, up 87.6% from last Wednesday's close at $1.45.
ProKidney has been soaring despite no news announcements, although the stock's rally began the day after $バーテックス・ファーマシューティカルズ(VRTX.US)$ unveiled plans to buy biotech $アルパイン・イミューン・サイエンシズ(ALPN.US)$ for $4.9 ...

$ナイキ(NKE.US)$$バーテックス・ファーマシューティカルズ(VRTX.US)$$マスターカード(MA.US)$$ビザ(V.US)$$エアビーアンドビー(ABNB.US)$
📊⚡️📊

$アディトクス(ADTX.US)$ to acquire Appili Tx
TuHURA Biosciences merger w/ $キンタラ・セラピューティクス(KTRA.US)$
$ジョンソン・エンド・ジョンソン(JNJ.US)$ to acquire $ショックウェーブ・メディカル(SWAV.US)$
$バーテックス・ファーマシューティカルズ(VRTX.US)$ to acquire $アルパイン・イミューン・サイエンシズ(ALPN.US)$
What companies will be next? 🤔

$バーテックス・ファーマシューティカルズ(VRTX.US)$$アルパイン・イミューン・サイエンシズ(ALPN.US)$
⚡ Vertex buys Alpine in a $4.9B deal 💰
⇨ Acquisition for $65/sh or $4.9B in cash 🤑
▪ Transaction closes in Q2 2024
⇨ Includes ALPN lead product, povetacicep (ALPN-303)
▪ best-in-class potential in patients with IgA nephropathy
▪ Ph3 to initiate in H2 2024